AI medical scribes
30 – 33Suki by 3
| Dimension | Commure Scribe | Suki | Gap |
|---|---|---|---|
| Access & pricePublished pricing, free tier, credential and regional eligibility, language coverage, and whether one clinician can evaluate the product without entering a sales process. | 8 | 4 | +4 |
| Documentation integrityICD-10 specificity, MEAT support, HCC recapture, E/M leveling and denial-risk checks — and whether each suggestion traces to verbatim text in the note so it survives an audit. | 5 | 8 | -3 |
| EHR & deploymentIntegration depth — native embed, authenticated API write-back, browser extension or copy-paste — plus enterprise rollout support and the procurement path. | 6 | 9 | -3 |
| Clinical reasoningWhether the product reasons about the encounter or only records it: ranked differential, problem-based assessment and plan, red-flag detection, and whether that reasoning is auditable rather than opaque. | 3 | 5 | -2 |
| Workflow & templatesTemplate depth and per-clinician customization, breadth of note types and specialties, non-physician coverage, and whether the tool can work on a note it did not draft. | 8 | 7 | +1 |
Commure Scribe
- Best for
- Allied-health and behavioural-health practices, where WebPT and TherapyNotes both have turn-key integrations, wanting a deeply configurable per-section template system. It is the only scribe scored here that ingests and restructures a note it did not draft.
- Limitation
- One-click EHR sync is Enterprise-gated, so self-serve buyers at this price hand off by copy-paste. E/M, LOS and HCC coding are enterprise-only, and Commure concedes on its own comparison page that its Citations traceability feature is publicly undocumented except for an article explaining how to switch it off.
- Price
- Published: $89/month, or $708/year — a $59/month equivalent
Suki
- Best for
- Health systems on Epic, Oracle Health, athenahealth or MEDITECH that need HCC-aware coding written straight into EHR fields rather than parked in a tab, plus the best-documented multilingual capture in the category at 80+ languages with published language IDs.
- Limitation
- No published price, no trial and no self-serve path, so an individual clinician cannot evaluate it at all. KLAS's own listing marks it limited market share on 18 organisations — too few live customers to qualify for the ranking Abridge has won twice — against Suki's claim of 400+ systems and partners.
- Price
- Not published; sales-led. The pricing page returns a 404.
